Shandong Provincial Hospital
π¨π³China
- Country
- π¨π³China
- Ownership
- Private
- Established
- 2022-03-18
- Employees
- -
- Market Cap
- -
- Website
- http://www.sph.com.cn
Clinical Trials
54
Active:4
Completed:6
Trial Phases
4 Phases
Phase 2:6
Phase 3:5
Phase 4:16
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (36 trials with phase data)β’ Click on a phase to view related trials
Phase 4
16 (44.4%)Not Applicable
9 (25.0%)Phase 2
6 (16.7%)Phase 3
5 (13.9%)An Empirical Study on the Mechanisms of Biopsychosocial Functional Improvement in Patients With Major Depressive Disorder Through Nature-Based Tourism Activities
Not Applicable
Not yet recruiting
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2025-09-18
- Last Posted Date
- 2025-10-02
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT07180342
- Locations
- π¨π³
Shandong Provincial Hospital Affiliated to Shandong First Medical, Shandong, China
Neoadjuvant QL1706 Therapy for ESCC
Phase 2
Recruiting
- Conditions
- Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06908382
- Locations
- π¨π³
Shandong Provincial Hospital, Jinan, Shandong, China
The Effect of the Application of Head Mounted Magnifying Glasses on Postoperative PTH Changes in Thyroid Surgery: Stage II
Not Applicable
Active, not recruiting
- Conditions
- Thyroid Surgery
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT06838728
- Locations
- π¨π³
Shandong Provincial Hospital, Jinan, Shandong, China
A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined with SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2
Not yet recruiting
- Conditions
- Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
- Interventions
- Drug: Neoadjuvant Therapy(QL1706+SOX Chemotherapy)Drug: Neoadjuvant Therapy(SOX Chemotherapy)Procedure: Radical surgery (D2)
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT06829797
Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2
Not yet recruiting
- Conditions
- Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
- Interventions
- Radiation: Neoadjuvant Therapy(5Γ3Gy radiotherapy)Drug: Neoadjuvant Therapy(tirelizumab, oxaliplatin, S-1)Procedure: Surgical treatmentDrug: Adjuvant therapy(SOX chemotherapy)
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06766578
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
No news found